This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shapiro, L. E. Articles by Surks, M. I. Search for Related Content PubMed PubMed Citation Articles by Shapiro, L. E. Articles by Surks, M. I.

Minimal Cardiac Effects in Asymptomatic Athyreotic Patients Chronically Treated with Thyrotropin-Suppressive Doses of L-Thyroxine¹

Divisions of Endocrinology, Diabetes and Metabolism, and Cardiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York 10467

Address all correspondence and requests for reprints to: Martin I. Surks, M.D., Montefiore Medical Center, Division of Endocrinology, 111 E. 210th Street, Bronx, New York 10467. E-mail: surks{at}aecom.edu.yu

Biondi, Fazio, and colleagues recently reported that long term T₄ treatment to suppress serum TSH markedly affects cardiac function. T₄-treated patients had more symptoms [12.2 ± 3.9 (±SD) vs. 4.2 ± 2.3 by quantitative questionnaire], higher mean heart rate, increased incidence of atrial extrasystoles, increased interventricular septal thickness and left ventricular mass index (LVMi), and significant diastolic dysfunction. The severity of cardiac abnormalities was highly correlated with scores of a rating scale used for assessing symptoms of thyrotoxicosis. We have duplicated their studies in 17 athyreotic patients (mean age, 45 ± 10 yr; range, 27–63 yr) without heart disease or hypertension whose dose of T₄ was titrated to suppress serum TSH to less than 0.01 µU/mL. The mean duration of T₄ treatment was 9.2 ± 5.4 yr. Controls were healthy volunteers matched for sex and age (±3 yr). The mean T₄ dose was 2.8 ± 0.9 µg/kg (0.192 ± 0.058 mg/day). By questionnaire, patients had minimal symptoms, although their symptom score was significantly greater than the control value (4 ± 3 vs. 2 ± 1; P < 0.05; maximum score, 36). No differences in mean heart rate or in atrial or ventricular extrasystoles were noted. In patients, indexes of systolic and diastolic function and interventricular septal thickness were similar to control values. The mean LVMi was normal in both groups. However, the mean LVMi in patients (117 ± 35 g/m²) was higher than that in controls (92 ± 31; P < 0.05). In conclusion, patients were minimally affected by TSH-suppressive doses of T₄. They had few symptoms and no increase in extrasystoles or basal heart rate. Based on current knowledge, the increase in LVMi observed in patients without associated significant systolic or diastolic abnormalities does not have clinical or prognostic importance. Therefore, in the absence of symptoms of thyrotoxicosis, patients treated with TSH-suppressive doses of L-T₄ may be followed clinically without specific cardiac laboratory studies.

This article has been cited by other articles:

				B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]

				A. R. Cappola Subclinical Thyroid Dysfunction and the Heart J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3404 - 3405. [Full Text] [PDF]

				A. Iqbal, H. Schirmer, P. Lunde, Y. Figenschau, K. Rasmussen, and R. Jorde Thyroid Stimulating Hormone and Left Ventricular Function J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3504 - 3510. [Abstract] [Full Text] [PDF]

				B Jarzab, D Handkiewicz-Junak, and J Wloch Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review Endocr. Relat. Cancer, December 1, 2005; 12(4): 773 - 803. [Abstract] [Full Text] [PDF]

				J. W. A. Smit, C. F. A. Eustatia-Rutten, E. P. M. Corssmit, A. M. Pereira, M. Frolich, G. B. Bleeker, E. R. Holman, E. E. van der Wall, J. A. Romijn, and J. J. Bax Reversible Diastolic Dysfunction after Long-Term Exogenous Subclinical Hyperthyroidism: A Randomized, Placebo-Controlled Study J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6041 - 6047. [Abstract] [Full Text] [PDF]

				G. J. Kahaly and W. H. Dillmann Thyroid Hormone Action in the Heart Endocr. Rev., August 1, 2005; 26(5): 704 - 728. [Abstract] [Full Text] [PDF]

				M. Casu, C. Cappi, V. Patrone, E. Repetto, M. Giusti, F. Minuto, and G. Murialdo Sympatho-vagal control of heart rate variability in patients treated with suppressive doses of L-thyroxine for thyroid cancer Eur. J. Endocrinol., June 1, 2005; 152(6): 819 - 824. [Abstract] [Full Text] [PDF]

				M. Dorr, B. Wolff, D. M. Robinson, U. John, J. Ludemann, W. Meng, S. B. Felix, and H. Volzke The Association of Thyroid Function with Cardiac Mass and Left Ventricular Hypertrophy J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 673 - 677. [Abstract] [Full Text] [PDF]

				B. Biondi, E. A. Palmieri, M. Klain, M. Schlumberger, S. Filetti, and G. Lombardi Subclinical hyperthyroidism: clinical features and treatment options Eur. J. Endocrinol., January 1, 2005; 152(1): 1 - 9. [Abstract] [Full Text] [PDF]

				E H Hoogendoorn, M den Heijer, A P J van Dijk, and A R Hermus Subclinical hyperthyroidism: to treat or not to treat? Postgrad. Med. J., July 1, 2004; 80(945): 394 - 398. [Abstract] [Full Text] [PDF]

				M. I. Surks, E. Ortiz, G. H. Daniels, C. T. Sawin, N. F. Col, R. H. Cobin, J. A. Franklyn, J. M. Hershman, K. D. Burman, M. A. Denke, et al. Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management JAMA, January 14, 2004; 291(2): 228 - 238. [Abstract] [Full Text] [PDF]

				S. Fazio, E. A. Palmieri, G. Lombardi, and B. Biondi Effects of Thyroid Hormone on the Cardiovascular System Recent Prog. Horm. Res., January 1, 2004; 59(1): 31 - 50. [Abstract] [Full Text]

				J. A. Sgarbi, F. G. Villaca, B. Garbeline, H. E. Villar, and J. H. Romaldini The Effects of Early Antithyroid Therapy for Endogenous Subclinical Hyperthyroidism in Clinical and Heart Abnormalities J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1672 - 1677. [Abstract] [Full Text] [PDF]

				B. Biondi, E. A. Palmieri, G. Lombardi, and S. Fazio Effects of Subclinical Thyroid Dysfunction on the Heart Ann Intern Med, December 3, 2002; 137(11): 904 - 914. [Abstract] [Full Text] [PDF]

				A C Al-Abadi Subclinical thyrotoxicosis Postgrad. Med. J., January 1, 2001; 77(903): 29 - 29. [Full Text]

				B. Biondi, E. A. Palmieri, S. Fazio, C. Cosco, M. Nocera, L. Saccà, S. Filetti, G. Lombardi, and F. Perticone Endogenous Subclinical Hyperthyroidism Affects Quality of Life and Cardiac Morphology and Function in Young and Middle-Aged Patients J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4701 - 4705. [Abstract] [Full Text]

				A D Toft and N A Boon GENERAL CARDIOLOGY: Thyroid disease and the heart Heart, October 1, 2000; 84(4): 455 - 460. [Full Text]

				G. Mercuro, M. G. Panzuto, A. Bina, M. Leo, R. Cabula, L. Petrini, F. Pigliaru, and S. Mariotti Cardiac Function, Physical Exercise Capacity, and Quality of Life during Long-Term Thyrotropin-Suppressive Therapy with Levothyroxine: Effect of Individual Dose Tailoring J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 159 - 164. [Abstract] [Full Text]

				S. Padayatty Concerning Minimal Cardiac Effects in Asymptomatic Athyreotic Patients Treated with Thyrotropin-Suppressive Doses of L-Thyroxine J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2607 - 2607. [Full Text]

				M. Nanna, L. E. Shapiro, R. Sievert, L. Ong, E. L. Ocampo, R. A. Chance, M. Lee, M. Nanna, K. Ferrick, and M. I. Surks Minimal Cardiac Effects in Asymptomatic Athyreotic Patients Chronically Treated with Thyrotropin-suppressive Doses of L-Thyroxine--Authors' Response J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2607a - 2608. [Full Text]

				A. R. Hermus and D. A. Huysmans Treatment of Benign Nodular Thyroid Disease N. Engl. J. Med., May 14, 1998; 338(20): 1438 - 1447. [Full Text] [PDF]